Cancer Vaccine

Pic:getty/drmicrobe

Building an mRNA giant: Moderna’s 7 priorities for 2023

By Rachel Arthur

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...

Pic:getty/oatawa

CureVac acquires Frame Cancer Therapeutics

By Rachel Arthur

CureVac has acquired Frame Cancer Therapeutics: with the German mRNA specialist planning to draw on Frame’s expertise in antigen identification and validation as it develops mRNA cancer vaccines.